ArticleCancers2026

Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients.

Charalampos Filippatos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.